Thursday, February 21, 2019 Daily Archives

Merck accessing cancer vaccine tech through $300m acquisition

by

Merck & Co. will acquire Immune Design for $300 million, adding cancer immunization and adjuvant systems technologies to its portfolio. The deal, expected to close early in the second quarter of 2019, sees Merck & Co. (known as MSD outside of North America) acquire late-stage Californian immunotherapy firm Immune Design for $5.85 (€5.15) per share in cash, totaling around $300 million. “Our primary interest to acquire Immune Design is related to their unique portfolio of approaches to cancer immunization and…

February 21, 2019

Big data-science for cell therapies: Mogrify boosted by $3.7m funding

by

All current cell therapies are failing on at least one of three key performance indicators: efficacy, safety and scalability, says Mogrify’s new CEO Darrin Disley. Cambridge, UK-based firm Mogrify is looking to transform the cell therapy space through its technology platform that it claims makes it possible to transform – or ‘transmogrify’ – any mature human cell type into any other without going through a pluripotent stem cell or progenitor cell state. The firm has bolstered its position by raising…

February 21, 2019